Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Co-development deal activity surged 1200% between the first and second halves of the March 2025–September 2026 tracking window, jumping from zero deals to 12 in just six months. The comparison periods — September 5, 2025 to March 5, 2026 (zero deals) versus March 5, 2026 to September 5, 2026 (12 deals) — reveal not a gradual uptick but a binary inflection point. The catalyst: Big Pharma is done paying full freight for late-stage assets and is instead demanding shared economics through co-development structures that split both risk and upside.

The Data — Co-Dev Deal Activity, Period over Period

Going from zero to 12 is technically infinite growth, but the 1200% figure captures the magnitude relative to the trailing baseline. The more important observation: this is not one or two outlier deals skewing the number. Twelve co-development agreements in six months, involving at least five distinct Big Pharma counterparties, constitutes a trend — not noise.

What's Driving the Trend

Three forces converged to make co-development the preferred deal architecture in mid-2026. First, capital discipline has become doctrine at every major pharma company. After several high-profile write-downs on fully acquired assets (Pfizer's Seagen integration headaches being the most cited), boards are pushing BD teams toward structures that keep capital deployed but limit downside exposure. Co-development deals accomplish exactly this: they cap upfront cash outlays while preserving optionality on commercialization rights. The math is straightforward — why pay $2B upfront for a Phase 2 asset when you can co-fund development for $400M and negotiate profit splits that approximate the same long-term economics?

Second, the competitive dynamics in oncology, immunology, and cardiometabolic have made speed-to-market existential. Traditional licensing deals with milestone-heavy structures create misaligned incentives — licensors want to de-risk before triggering expensive Phase 3 starts, while licensees want to accelerate timelines. Co-development agreements align both parties around a single development plan with shared governance, eliminating the friction that slows milestone-based partnerships. In a world where three companies may be racing to the same target, six months of alignment delays can be the difference between a blockbuster and a footnote.

Third — and this is underappreciated — the co-development structure has become a competitive weapon in deal sourcing. Biotechs with differentiated assets are increasingly choosing partners who offer co-development terms over those offering larger upfronts with full rights transfer. The reason is retention of economics: a co-development deal with a 50/50 profit split on a potential $5B peak-sales asset is worth far more to a biotech's shareholders than a $500M upfront with single-digit royalties. Smart BD teams at pharma companies have recognized this and are leading with co-dev term sheets to win competitive processes. Check how your proposed structures compare against the current market using our Deal Benchmarks.

Notable Deals

The pattern here is unmistakable: these are not small biotechs partnering with Big Pharma. These are pharma-to-pharma co-development deals — the kind of transaction that barely existed 18 months ago. The AstraZeneca-Merck agreement and the Janssen-AbbVie deal represent a new category: large-cap companies choosing to share development risk on assets that either party could plausibly fund alone. This is not about capital constraints. It is about portfolio construction, development velocity, and commercial reach.

The Amgen-BeiGene and Amgen-Novartis deals are particularly instructive. Amgen's willingness to co-develop rather than simply out-license or retain full ownership suggests the company views shared governance as a net positive — likely because it accelerates geographic access (BeiGene's China infrastructure) or adds complementary commercial capabilities (Novartis's global oncology footprint). These deals confirm that co-development licensing in 2026 is a strategic choice, not a concession made from weakness.

The clustering of five major deals within a 48-hour window (July 18–20) also warrants attention. Whether coordinated or coincidental, it signals that multiple deal teams were working these structures in parallel throughout Q2 2026, and that the market reached a critical mass of precedent transactions that gave legal and commercial teams comfort to close.

What This Means for BD Teams Right Now

If you are a biotech with a Phase 1b or Phase 2 asset in a competitive therapeutic area, this is a seller's market for co-development terms — but only if you structure the conversation correctly. The data shows that pharma partners are willing to engage co-dev frameworks, which means you can push for favorable profit splits (50/50 or even 60/40 in your favor for U.S. rights) without losing serious bidders. The leverage comes from the fact that pharma BD teams are being told by their own leadership to bring back co-dev structures, not traditional licenses. Use that internal mandate to your advantage.

If you are on the pharma side, recognize that the co-dev trend has compressed your competitive moat. When every major player is offering co-development terms, the differentiator shifts to non-financial factors: development expertise, regulatory track record, commercial infrastructure, and speed of decision-making. The teams that win competitive co-dev processes in H2 2026 will be the ones that can commit to a development plan and JDC governance structure in the term sheet, not six months after signing. Use Solidus to model risk-adjusted returns on co-development structures before entering diligence.

Deal structures to watch: co-development with opt-out provisions is emerging as the hybrid model that gives pharma downside protection while giving biotechs confidence in partner commitment. Expect to see more deals where the pharma partner commits to 50% of Phase 2 costs with a Phase 3 opt-out that converts the arrangement to a royalty-bearing license. This gives the biotech a funded Phase 2 and the pharma company a real option on Phase 3 — a structure that is better aligned than either a pure co-dev or a traditional license.

Benchmark your deal against current market rates. Whether you are structuring a co-development agreement or evaluating a competing term sheet, the economics need to reflect mid-2026 realities — not 2024 precedents. Run your numbers through the Ambrosia calculator to see where your deal stands relative to the 12 co-dev transactions closed this period.